skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Risk management in the treatment of type 2 diabetes with pioglitazone

Review

(3615) Views  (830) Full article downloads

Authors: Giuseppe Derosa, Sibilla AT Salvadeo

Published Date July 2009 Volume 2009:2 Pages 51 - 60
DOI: http://dx.doi.org/10.2147/DMSO.S3950

Giuseppe Derosa, Sibilla AT Salvadeo

Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Introduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. Insulin-resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Pioglitazone is an insulin-sensitizing agent available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of pioglitazone in achieving metabolic control and reducing cardiovascular morbidity and mortality.

Aim: The purpose of this article is to review the effectiveness and tolerability of pioglitazone in the prevention and management of atherosclerosis in patients with type 2 diabetes.

Evidence review: We reviewed the main monotherapy and comparative studies of pioglitazone, and particularly the recent evidence in the field of atherosclerosis and cardiovascular prevention.

Place in therapy: The current evidence shows that pioglitazone is an effective option in the treatment of type 2 diabetes. More studies are needed to establish a role for pioglitazone in atherosclerosis prevention beyond glycemic control.

Keywords: pioglitazone, diabetes mellitus, glycated hemoglobin, cardiovascular prevention






 

Other articles by Professor Giuseppe Derosa



Readers of this article also read:

Comorbidity and glycemia control among patients with type 2 diabetes in primary care
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Fixed combination of repaglinide and metformin in the management of type 2 diabetes
Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: central plus peripheral nervous system mechanisms
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
Clinical and behavioral factors associated with management outcome in hospitalized patients with diabetic foot ulcer
Erratum
Insulin detemir for the treatment of obese patients with type 2 diabetes
Obesity: considerations about etiology, metabolism, and the use of experimental models
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio